Inventiva (NASDAQ:IVA) Releases Quarterly Earnings Results

Inventiva (NASDAQ:IVA) posted its quarterly earnings data on Monday. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.57), FiscalAI reports. The firm had revenue of $0.01 million during the quarter, compared to analyst estimates of $8.67 million.

Inventiva Stock Down 4.2%

Inventiva stock traded down $0.24 during midday trading on Monday, reaching $5.48. The company’s stock had a trading volume of 286,516 shares, compared to its average volume of 434,234. The business has a 50-day simple moving average of $6.30 and a 200-day simple moving average of $5.38. Inventiva has a fifty-two week low of $2.85 and a fifty-two week high of $7.98.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. HC Wainwright set a $24.00 target price on Inventiva and gave the company a “buy” rating in a report on Wednesday, January 28th. UBS Group started coverage on Inventiva in a research report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 price target on the stock. Barclays started coverage on Inventiva in a research report on Tuesday, January 27th. They set an “overweight” rating and a $18.00 price objective for the company. Truist Financial began coverage on shares of Inventiva in a research note on Thursday, March 19th. They set a “buy” rating and a $13.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inventiva in a research note on Thursday, January 22nd. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Inventiva presently has an average rating of “Buy” and a consensus price target of $16.56.

Institutional Investors Weigh In On Inventiva

Hedge funds and other institutional investors have recently made changes to their positions in the business. Creative Planning acquired a new position in Inventiva in the second quarter valued at approximately $32,000. Virtu Financial LLC acquired a new stake in Inventiva during the fourth quarter worth approximately $60,000. XTX Topco Ltd purchased a new stake in shares of Inventiva during the 4th quarter worth approximately $84,000. Cerity Partners LLC acquired a new position in shares of Inventiva in the 4th quarter valued at $93,000. Finally, NewEdge Advisors LLC acquired a new position in shares of Inventiva in the 3rd quarter valued at $116,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.